Dyadic, Fermbox Bio Debut Animal-Origin-Free Recombinant DNase I Under Expanded Collaboration
Dyadic and Fermbox Bio have launched animal-origin-free Recombinant DNase I (RNase-free), the first commercial product from their expanded collaboration, marking Dyadic’s shift from platform development toward recurring revenue generation. Research-grade DNase I is now available, with a cGMP-grade version in development for biopharmaceutical manufacturing and cell and gene therapy applications.
1. Commercial Launch of RNase-Free DNase I
Dyadic Applied BioSolutions and Fermbox Bio have commercially launched animal-origin-free Recombinant DNase I (RNase-free) in research-grade form. A cGMP-grade version is under development to support biopharmaceutical manufacturing and cell and gene therapy applications, representing the first product from their 2025 expanded collaboration.
2. Collaboration Framework
Under the collaboration, Dyadic supplies its proprietary high-yield fungal microbial expression platforms and development support, while Fermbox Bio leads downstream process development, scale-up and biomanufacturing. The partnership aims for global commercialization to serve research and biomanufacturing customers.
3. Pipeline Plans for 2026
Recombinant DNase I is the first in a planned series of recombinant enzymes scheduled for commercial launch throughout 2026, including α-lactalbumin, transferrin, human FGF-2, lactoferrin and other proteins targeting cell culture media, molecular biology reagents and advanced biologics manufacturing.